Telehealth platforms are approaching compounding pharmacies with marketing, staffing, and fulfillment arrangements that route prescriptions for semaglutide, tirzepatide, and hormone therapies directly to a preferred pharmacy. These deals can be lawful, but the fee structure behind them determines whether the arrangement is an ordinary vendor relationship or a federal kickback under the Anti-Kickback Statute. A pharmacy that pays a platform per filled prescription, or accepts a discounted rate in exchange for exclusive access to its prescribers, can face civil penalties, False Claims Act liability, and exclusion from federal health care programs, whatever framework, 503A/503B, governs the compounding itself. The framework a pharmacy operates under also changes the volume the platform can drive, since a 503B outsourcing facility can fill in anticipation of orders in a way a 503A pharmacy generally cannot, and that volume difference changes the kickback analysis.
How Referral Fees Trigger the Anti-Kickback Statute
The federal Anti-Kickback Statute, 42 U.S.C. Section 1320a-7b(b), makes it a crime to knowingly offer, pay, solicit, or receive remuneration to induce referrals of business reimbursable under a federal health care program. A telehealth-pharmacy arrangement does not have to be labeled a referral fee to raise exposure. A marketing fee, a data-licensing fee, or a per-consultation charge that rises and falls with the volume of prescriptions the pharmacy ultimately fills functions the same way a referral fee would, and enforcement authorities analyze it on substance rather than the label in the contract. The statute also carries a civil analog, and conduct that implicates the criminal statute typically supports a False Claims Act theory as well once federal program dollars are involved.
What the OIG's Telemedicine Fraud Alert Flags
The HHS Office of Inspector General's July 2022 Special Fraud Alert identified suspect characteristics common to fraudulent telemedicine arrangements, issued after a coordinated enforcement action involving billions of dollars in fraudulent telehealth billing. Two of the flagged patterns apply directly to pharmacy partnerships: compensation to the ordering party that is tied to the volume of items or services ordered, and prescribing based on limited or no direct interaction between the prescriber and the patient. Enforcement attention on GLP-1 class compounding has followed this same pattern, with government focus falling on the commercial relationships behind high-volume prescribing at least as heavily as on the compounding itself. A pharmacy that never structured its own platform agreement can still be drawn into scrutiny of the prescriber's arrangement, because pharmacy claims data is often what first establishes the volume pattern.
Structuring the Agreement to Fit a Safe Harbor
The Anti-Kickback Statute's personal services and management contracts safe harbor, at 42 C.F.R. Section 1001.952(d), offers the clearest structural path for a telehealth-pharmacy relationship: a written agreement, a term of at least one year, and aggregate compensation that is set in advance, consistent with fair market value, and not determined in a way that accounts for the volume or value of referrals. A flat monthly platform-access fee can fit that shape. A per-prescription or percentage-of-revenue fee generally cannot. Pharmacies that also fill prescriptions for hormone therapies involving controlled substances face a second layer of exposure, since the temporary DEA flexibility allowing a controlled-substance prescription without a prior in-person examination is currently extended only through December 31, 2026, after which a prescriber-patient relationship formed entirely through a telehealth platform may no longer support a valid prescription. None of this substitutes for the pharmacy's own cGMP, USP 797/800 sterile compounding, and beyond-use date obligations, which are reviewed separately from the commercial arrangement that brought the prescription in the door.
A fee that rises when a pharmacy fills more prescriptions is not a marketing charge. It is the kind of volume-based remuneration the Anti-Kickback Statute was written to reach.
Why Early Legal Counsel Is Critical
It is critical that healthcare providers promptly retain experienced healthcare defense counsel before entering or restructuring a telehealth referral arrangement. Early legal intervention can protect the provider's rights, structure the arrangement to fit an available safe harbor, avoid inadvertent admissions if already under review, and preserve relevant defenses. Delaying legal representation can significantly affect the outcome of a matter and expose the provider to unnecessary risk.
How Health Law Alliance Can Help
Health Law Alliance has represented 2,500+ clients over 25+ years, including compounding pharmacies negotiating and defending telehealth partnership agreements. Our compounding pharmacy attorneys review proposed platform contracts against the available Anti-Kickback Statute safe harbors before they are signed, and represent pharmacies already facing a government inquiry into a referral arrangement. Contact Health Law Alliance for a free, confidential consultation.
